Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the value of biosimilars in oncology.
Maryam Nemati Shafaee, MD
Advertisement
Articles by Maryam Nemati Shafaee, MD
Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the PERSEPHONE trial in women with early-stage HER2-positive breast cancer.
Advertisement
Latest Updated Articles
Dr. Shafaee on the Value of BiosimilarsAugust 1st 2018
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
2
Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC
3
Dr Morgans on the Design of the ARACOG Trial in Prostate Cancer
4
Introduction and Frontline Treatment Options for EGFR-Mutated NSCLC
5